Search the Newsreel

T. Rowe Price Associates (TWST) discloses 3.63M-share Twist Bioscience position

T. Rowe Price Associates has reported a beneficial ownership of 3,634,470 shares of Twist Bioscience Corp. (TWST), representing a 5.8% stake in the company's common stock. The firm holds sole voting power over 3,520,536 shares and sole dispositive power over all 3,634,470 shares, as …

Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Rating of "Buy" by Analysts

Kyntra Bio Confronts Nasdaq Listing Risk as Asset and Revenue Shortfall Threatens Global Select Status

Puma Biotechnology (NASDAQ:PBYI) Upgraded at Wall Street Zen

Wall Street Zen upgraded Puma Biotechnology (NASDAQ:PBYI) from a "buy" to a "strong-buy" rating, despite the broader analyst consensus remaining "hold" with a $6.00 price target. The company reported strong quarterly earnings, beating EPS and revenue estimates, though insiders have sold a significant number …

iBio (NASDAQ:IBIO) Rating Increased to Hold at Wall Street Zen

Wall Street Zen has upgraded iBio (NASDAQ:IBIO) from a "sell" to a "hold" rating, though the broader analyst consensus remains a "Buy" with a $5.00 average price target. The company recently reported a quarterly loss of $0.07 per share, missing estimates, and its stock …

Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold

Wall Street Zen has upgraded Vor Biopharma (NASDAQ:VOR) from a "sell" to a "hold" rating. Despite this, the overall analyst consensus for Vor Biopharma remains a "Moderate Buy" with an average price target of $43.38, though the company's stock trades significantly below its 52-week …

IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen downgraded IDEAYA Biosciences (NASDAQ:IDYA) from "hold" to "sell," despite the broader analyst consensus remaining a "Moderate Buy" with an average price target of $50.12. The company's shares opened at $36.30, and it recently reported a quarterly loss of $1.22 per share, …

Arbutus Biopharma (NASDAQ:ABUS) Cut to Hold at Wall Street Zen

Wall Street Zen downgraded Arbutus Biopharma (NASDAQ:ABUS) from a "buy" to a "hold" rating, though Weiss Ratings simultaneously upgraded it from "sell" to "hold." The biopharmaceutical company holds a consensus "Moderate Buy" rating and a $5.00 price target. Despite missing quarterly EPS estimates by …

Maxim Group Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $8

Maxim Group has reiterated its Buy rating for Palisade Bio (PALI.US) and maintained its target price at $8. This indicates continued confidence from the firm in the company's prospects.

Upstream Bio (NASDAQ:UPB) Lowered to "Strong Sell" Rating by Wall Street Zen

Wall Street Zen has downgraded Upstream Bio (NASDAQ:UPB) to a "Strong Sell" rating from "Sell," intensifying cautious sentiment around the clinical-stage biotech company. Despite the downgrade, analyst opinions remain mixed, with four "Buy" ratings, two "Hold," and one "Sell," resulting in a consensus "Hold" …

Ajooni Biotech standalone net profit declines 44.87% in the June 2026 quarter

How Investors May Respond To BioCryst (BCRX) Profit Swing, Raised Revenue Outlook And New ESOP Shares

BioCryst Pharmaceuticals reported a significant profit swing in Q2 2026, with revenue of US$218.25 million and net income of US$78.4 million, prompting a raised full-year revenue outlook to US$690 million–US$715 million. Despite this strong quarter, the company still faces a substantial year-to-date net loss …

Annovis Bio (ANVS) posts $32.4M loss and warns on going-concern risk

Annovis Bio reported a six-month net loss of $32.4 million, primarily due to increased research and development expenses for its Alzheimer's and Parkinson's disease clinical trials. The company's cash and cash equivalents stood at $18.7 million, with management warning that these funds are only …

Gufic BioSciences consolidated net profit rises 70.70% in the June 2026 quarter

Vor Biopharma (VOR) sees Frazier Life Sciences entities report under 5% ownership

Frazier Life Sciences-affiliated funds have filed an amended Schedule 13G indicating beneficial ownership of less than 5% of Vor Biopharma Inc. common stock. Frazier Life Sciences Public Fund, L.P. holds 4.2% of the class, while Frazier Life Sciences XII, L.P. holds 0.5%, and Frazier …

Why (ATRA) Price Action Is Critical for Tactical Trading

This article analyzes Atara Biotherapeutics Inc. (NASDAQ: ATRA) for tactical trading, highlighting a strong near and mid-term sentiment despite a weak long-term outlook. It identifies an exceptional 234.0:1 risk-reward setup targeting a 70.2% gain against 0.3% risk. The analysis also provides specific institutional trading …

IBRX Stock To Open Week On A High? Chairman Teases Anktiva’s 3-Year Expansion Plans, Hints At Cancer Breakthrough

Woodline Partners (SABS) discloses 5.46M-share beneficial stake in SAB Biotherapeutics

Woodline Partners LP has filed an amended Schedule 13G, disclosing a beneficial ownership of 5,455,355 shares, or 6.8%, of SAB Biotherapeutics, Inc. common stock. This stake includes common shares and shares issuable from Series B Preferred Stock underlying Enrollment and Data Release Warrants. The …

Skye Bioscience to acquire Redx Pharma in $125M deal By Investing.com

Skye Bioscience announced its definitive agreement to acquire Redx Pharma through a scheme of arrangement under U.K. law for an approximate $125 million deal. The merged entity will be known as Fibrx Therapeutics Inc., trading on Nasdaq, and will be led by Redx's current …

Nasdaq, S&P 500 Futures Rise Ahead Of Nvidia Earnings, Fed Minutes: Why TSLA, SLS, IBRX, CAVA, POET, BA Are In Focus

BioRestorative Therapies suspends shipments of ExoCR and BioX products for review

BioRestorative Therapies (NASDAQ:BRTX) has suspended all orders and shipments of its ExoCR and BioX biocosmeceutical product lines, effective August 7, pending a business review and regulatory assessment. The company, which has a market cap of $5.61 million and generated only $360,000 in revenue in …

Theravance Biopharma (TBPH): Newtyn discloses 6.7% holdings in amended 13G/A

Newtyn Management, LLC has disclosed a 6.7% beneficial ownership in Theravance Biopharma (TBPH) through an amended Schedule 13G filing. While Newtyn TE Partners, LP, a part of Newtyn Management, has reduced its holdings to below the 5% reporting threshold, Newtyn Management itself remains above …

Form 8K BioRestorative Therapies Inc For: 14 August By Investing.com

This article reports that BioRestorative Therapies Inc. filed a Form 8K on August 14th. The filing is brief and primarily serves as an announcement of this corporate action.

Krystal Biotech(KRYS.US) Director Sells US$8.23 Million in Common Stock

Krystal Biotech (KRYS.US) Director, Daniel Meyer, sold 84,200 shares of common stock on August 13, 2026, for a total of $8.23 million. The shares were sold at an average price of $97.75. Following this transaction, Meyer directly owns 10,000 shares of the company.

Swedish Orphan Biovitrum (OM:SOBI) Following Its Lacutamab Deal And The Undervalued Narrative

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why Swedish Orphan Biovitrum Stock Is Back In Focus Swedish Orphan Biovitrum (OM:SOBI) has drawn fresh attention after a new partnership with Innate Pharma …

Orchestra BioMed (OBIO) director uses 5,145 shares to cover RSU tax withholding

Orchestra BioMed Holdings, Inc. director Eric S. Fain reported an indirect disposition of 5,145 common stock shares on August 12, 2026. These shares were withheld by the company to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs) and no …

TuHURA Biosciences Expect Preliminary Results From IR Study IFX-2.0 With Keytruda for Deep Seated MCC in 1H2027 >HURA

TuHURA Biosciences anticipates preliminary results from its IFX-2.0 study, which combines IFX-2.0 with Keytruda for treating deep-seated Merkel Cell Carcinoma (MCC). These results are expected in the first half of 2027. This study represents a key milestone for TuHURA Biosciences in its development of …

Ikarian Capital (CNTB) discloses 6.9% Connect Biopharma holding on Schedule 13G/A

Ikarian Capital, LLC and Neil Shahrestani have disclosed a 6.9% beneficial ownership in Connect Biopharma Holdings Limited Ordinary Shares through a Schedule 13G/A filing. This ownership amounts to 4,338,534 shares, based on 62,974,309 Ordinary Shares outstanding as of July 31, 2026. The filing indicates …

Boundless Bio (BOLD): ADAR1 Capital discloses 8.8% beneficial ownership stake

ADAR1 Capital Management, LLC has disclosed an 8.8% beneficial ownership stake in Boundless Bio, Inc. (BOLD), totaling 1,968,216 shares. This stake, based on 22,475,000 shares outstanding as of June 30, 2026, is subject to shared voting and dispositive power by ADAR1 Capital Management and …

Insider Selling: Cue Biopharma (NASDAQ:CUE) CEO Sells 18,258 Shares

Cue Biopharma CEO Shao-Lee Lin sold 18,258 shares of the company's stock for over $522,000 to cover tax withholding obligations from vested equity awards. This sale reduced her ownership by 2.52%, following a previous sale of 40,000 shares for $1.08 million. The company recently …

Cue Biopharma CEO Lin sells shares worth $1.6 million

Cue Biopharma CEO Lin Shao-Lee sold shares worth $1.6 million, primarily to cover tax obligations from vested restricted stock units, not as discretionary sales. Concurrently, Mr. Lin acquired 109,179 shares from vested performance stock units. The company has also appointed a new Chief Medical …

Insider plans 58,258-share stock sale (NASDAQ: CUE) under Rule 144

An insider of Cue Biopharma (NASDAQ: CUE) has filed a Rule 144 notice to sell up to 58,258 shares of common stock. These shares originated from restricted stock units that vested on August 1, 2026. The sale is planned to occur in two tranches …

Senti Biosciences Holdings Inc. (SNTI) Stock Price | Live Quotes & Charts | NASDAQ

Bright Minds Biosciences (NASDAQ:DRUG) Issues Quarterly Earnings Results

Bright Minds Biosciences (NASDAQ:DRUG) reported quarterly earnings per share of ($0.17), significantly surpassing analysts' consensus estimate of ($1.28). Following the announcement, shares fell 2.0% to $76.44. Analysts maintain a generally positive outlook on the stock, with an average "Buy" rating and a consensus price …

Moleculin Biotech Releases Q2 2026 Financial Results

Moleculin Biotech (MBRX) reported a net loss of $7.6 million for Q2 2026, with a significant improvement in loss per share, narrowing to $1.40 from $12.25 in Q2 2025. The company, focused on therapeutic candidates for tumors and viruses, generated no revenue but continued …

Cue Biopharma (NASDAQ:CUE) Posts Quarterly Earnings Results, Misses Estimates By $22.45 EPS